These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 20561040)

  • 21. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
    Koch-Henriksen N; Sorensen PS; Bendtzen K; Flachs EM
    Mult Scler; 2009 May; 15(5):601-5. PubMed ID: 19299439
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neutralizing antibodies, MxA expression and MMP-9/TIMP-1 ratio as markers of bioavailability of interferon-beta treatment in multiple sclerosis patients: a two-year follow-up study.
    Garcia-Montojo M; Dominguez-Mozo MI; de las Heras V; Bartolome M; Garcia-Martinez A; Arroyo R; Alvarez-Lafuente R
    Eur J Neurol; 2010 Mar; 17(3):470-8. PubMed ID: 20050906
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies.
    Scagnolari C; Duda P; Bagnato F; De Vito G; Alberelli A; Lavolpe V; Girardi E; Durastanti V; Trojano M; Kappos L; Antonelli G
    J Neurol; 2007 May; 254(5):597-604. PubMed ID: 17420930
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1.
    Gilli F; Marnetto F; Caldano M; Sala A; Malucchi S; Capobianco M; Bertolotto A
    Mult Scler; 2006 Feb; 12(1):47-57. PubMed ID: 16459719
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gene expression profiling of relevant biomarkers for treatment evaluation in multiple sclerosis.
    Hong J; Zang YC; Hutton G; Rivera VM; Zhang JZ
    J Neuroimmunol; 2004 Jul; 152(1-2):126-39. PubMed ID: 15223245
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of interferon-beta on co-signaling molecules: upregulation of CD40, CD86 and PD-L2 on monocytes in relation to clinical response to interferon-beta treatment in patients with multiple sclerosis.
    Wiesemann E; Deb M; Trebst C; Hemmer B; Stangel M; Windhagen A
    Mult Scler; 2008 Mar; 14(2):166-76. PubMed ID: 17942524
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A case study on the effect of neutralizing antibodies to interferon beta 1b in multiple sclerosis patients followed for 3 years with monthly imaging.
    Chiu AW; Ehrmantraut M; Richert ND; Ikonomidou VN; Pellegrini S; McFarland HF; Frank JA; Bagnato F
    Clin Exp Immunol; 2007 Oct; 150(1):61-7. PubMed ID: 17666095
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neutralizing antibodies in multiple sclerosis patients treated with 375 micrograms interferon-beta-1b.
    Durelli L; Barbero P; Cucci A; Ferrero B; Ricci A; Contessa G; De Mercanti S; Ripellino P; Lapuma D; Viglietta E; Bergui M; Versino E; Clerico M;
    Expert Opin Biol Ther; 2009 Apr; 9(4):387-97. PubMed ID: 19278300
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dynamics of interferon-beta modulated mRNA biomarkers in multiple sclerosis patients with anti-interferon-beta neutralizing antibodies.
    Santos R; Weinstock-Guttman B; Tamaño-Blanco M; Badgett D; Zivadinov R; Justinger T; Munschauer F; Ramanathan M
    J Neuroimmunol; 2006 Jul; 176(1-2):125-33. PubMed ID: 16698090
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical effect of neutralizing antibodies to interferon beta that persist long after cessation of therapy for multiple sclerosis.
    van der Voort LF; Gilli F; Bertolotto A; Knol DL; Uitdehaag BM; Polman CH; Killestein J
    Arch Neurol; 2010 Apr; 67(4):402-7. PubMed ID: 20142519
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dynamic T-lymphocyte chemokine receptor expression induced by interferon-beta therapy in multiple sclerosis.
    Krakauer M; Sorensen PS; Khademi M; Olsson T; Sellebjerg F
    Scand J Immunol; 2006 Aug; 64(2):155-63. PubMed ID: 16867161
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-interferon beta antibody titers strongly correlate between two bioassays and in vivo biomarker expression, and indicates that a titer of 150 TRU/mL is a biologically functional cut-point.
    Hermanrud C; Ryner ML; Engdahl E; Fogdell-Hahn A
    J Interferon Cytokine Res; 2014 Jul; 34(7):498-504. PubMed ID: 24444338
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacogenetics of MXA SNPs in interferon-beta treated multiple sclerosis patients.
    Weinstock-Guttman B; Tamaño-Blanco M; Bhasi K; Zivadinov R; Ramanathan M
    J Neuroimmunol; 2007 Jan; 182(1-2):236-9. PubMed ID: 17126411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neutralizing antibodies reduce MxA protein induction in interferon-beta-1a-treated MS patients.
    Vallittu AM; Halminen M; Peltoniemi J; Ilonen J; Julkunen I; Salmi A; Erälinna JP;
    Neurology; 2002 Jun; 58(12):1786-90. PubMed ID: 12084878
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development and characterization of a non-cell-based assay to assess the presence of neutralizing antibodies to interferon-beta in clinical samples.
    Cludts I; Meager A; Thorpe R; Wadhwa M
    J Immunol Methods; 2013 Sep; 395(1-2):37-44. PubMed ID: 23831137
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients.
    van Baarsen LG; Vosslamber S; Tijssen M; Baggen JM; van der Voort LF; Killestein J; van der Pouw Kraan TC; Polman CH; Verweij CL
    PLoS One; 2008 Apr; 3(4):e1927. PubMed ID: 18382694
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vivo bioactivity of interferon-beta in multiple sclerosis patients with neutralising antibodies is titre-dependent.
    Sominanda A; Hillert J; Fogdell-Hahn A
    J Neurol Neurosurg Psychiatry; 2008 Jan; 79(1):57-62. PubMed ID: 17911184
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preserved in vivo response to interferon-alpha in multiple sclerosis patients with neutralising antibodies against interferon-beta (REPAIR study).
    Magyari M; Bach Søndergaard H; Sellebjerg F; Soelberg Sørensen P
    Mult Scler Relat Disord; 2013 Apr; 2(2):141-6. PubMed ID: 25877635
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impression of clinical worsening fails to predict interferon-beta neutralizing antibody status.
    Rot U; Sominanda A; Fogdell-Hahn A; Hillert J
    J Int Med Res; 2008; 36(6):1418-25. PubMed ID: 19094453
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients.
    Bertolotto A; Gilli F; Sala A; Capobianco M; Malucchi S; Milano E; Melis F; Marnetto F; Lindberg RL; Bottero R; Di Sapio A; Giordana MT
    Neurology; 2003 Feb; 60(4):634-9. PubMed ID: 12601105
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.